文献速递瓣膜外科

On-X双叶二尖瓣的长期结局:661例患者长达17年的临床事件

Long-term outcomes with the On-X bileaflet mitral valve: clinical events up to 17 years in 661 patients.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

这项回顾性观察研究纳入2001至2018年间在西班牙2个心脏外科中心接受On-X双叶机械二尖瓣置换的661例患者,平均随访5.6年(范围0-17.4年)。5年、10年、15年生存率分别为85%、71%、63%,手术死亡率为7.3%(48/661),免于再手术率分别为97%、95%、92%。作者结论为患者长期生存良好且免于瓣膜相关事件。

要点

  • 661例On-X二尖瓣置换患者平均随访5.6年,5/10/15年生存率85%/71%/63%。
  • 手术死亡率7.3%(48/661),全因死亡线性化率1.3%/患者年。
  • 5/10/15年免于再手术97%/95%/92%,免于抗凝相关事件94%/89%/89%。

核心结论

  • 本研究中患者表现出良好的长期生存和免于瓣膜相关事件。

研究设计与样本

  • 回顾性观察研究,纳入2001至2018年间在西班牙2个心脏外科中心接受On-X(Standard或Conform-X)二尖瓣置换的所有患者,共661例(平均年龄63.1±10.9岁,女性63%)。

主要发现

  • 平均随访5.6年(范围0-17.4年),5年、10年、15年生存率分别为85%、71%、63%。
  • 手术死亡率为7.3%(48/661),全因死亡线性化率为1.3%/患者年。
  • 5年、10年、15年免于再手术率分别为97%、95%、92%,免于抗凝相关事件率分别为94%、89%、89%。
  • 多变量分析显示死亡风险随总住院时间、年龄、吸烟史、重度肺动脉高压和永久起搏器而增加。
  • 接受On-X 25 mm瓣膜的患者较接受其他On-X瓣膜尺寸的患者长期生存降低,可能归因于潜在危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study reports long-term clinical outcomes-up to 17 years-among patients undergoing mitral valve replacement with the On-X bileaflet mechanical valve. Prior data regarding long-term outcomes with the On-X mitral valve have been limited. METHODS: This retrospective observational study included all patients who underwent mitral valve replacement with the On-X (Standard or Conform-X) valve at 2 major Spanish cardiac surgery centres between 2001 and 2018. The primary study end point was freedom from death. The secondary study end points included surgical mortality and freedom from any valve-related events. Data were obtained from an institutional database, medical records review, direct telephone interviews or the Spanish population registry. Statistical and Kaplan-Meier analyses were performed. RESULTS: A total of 661 patients (mean age 63.1 ± 10.9 years, 63% female) were followed for a mean of 5.6 years (range, 0-17.4 years). Survival at 5, 10 and 15 years was 85%, 71% and 63%, respectively. Surgical mortality was 7.3% (48/661). The linearized rate of global mortality was 1.3% patient-year. Freedom from reoperation was 97%, 95% and 92% at 5, 10 and 15 years, respectively; freedom from anticoagulation-related events was 94%, 89% and 89%, respectively. Multivariable analysis showed that mortality increased with total length of stay, age, smoking history, severe pulmonary hypertension and a permanent pacemaker. Patients who received the On-X 25 -mm valve had decreased long-term survival relative to patients who received other On-X valve sizes, possibly due to underlying risk factors. CONCLUSIONS: Patients in this study showed good long-term survival and freedom from valve-related events.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Reyes G, Muñoz D, Monguio E, et al. Long-term outcomes with the On-X bileaflet mitral valve: clinical events up to 17 years in 661 patients. Eur J Cardiothorac Surg. 2022. PMID: 35348660. doi:10.1093/ejcts/ezac157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。